openPR Logo
Press release

Novel Drug Delivery to be discussed at SMi’s Ophthalmic Drugs Conference and Focus Day 2019

10-22-2019 12:11 PM CET | Associations & Organizations

Press release from: SMI

Ophthalmic Drugs Conference and Focus Day 2019

Ophthalmic Drugs Conference and Focus Day 2019

SMi Reports: Industry leaders confirmed to present on the Focus Day for the upcoming Ophthalmic Drugs conference, in London

With less than 4 weeks until SMi Group’s 3rd annual Ophthalmic Drugs conference taking place on the 18th- 20th November 2019 in London, the event aims to provide great peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more.

Alongside the conference, a Pre-conference Focus Day will proceed, in which the event theme will be on ‘Novel Drug Delivery though a Complex Barrier’. The focus day will emphasise on alternative delivery approaches to replace intravitreal drug delivery and novel drug development. Also, industry leaders will explore innovations in R&D of novel delivery methods; mechanisms including implants for IOP control; an antagonist prodrug for sustained reduction of intraocular pressure and alternatives to intravitreal delivery.

As there is less than 4 weeks remaining, places are increasingly limited. Interested parties are urged to secure their place at www.ophthalmicdrugs.com/openpr8

Highlights for 2020:

Safety and Efficacy of a Novel Intracapsular Drug Delivery Platform

- iVeena has developed an intracapsular drug delivery platform that enables bi-directional drug delivery to anterior and posterior eye segments
- The initial platform technology application is IVMED-20, a bioerodible dexamethasone delivery implant placed during cataract surgery to prophylax cystoid macular edema, as well as, control inflammation and pain from the procedure
Michael Burr, Vice President of Product Development, iVeena

This year’s Focus Day Chairman will be MHRA’s Medical Assessor, Peter Morgan-Warren, on ‘Regulatory perspectives on novel ocular drug delivery’ covering:

- Novel ocular drug delivery and the regulatory framework – clinical considerations
- Combination products, devices and borderline products

For the full speaker line-up, as well as the latest event details, the brochure is available at www.ophthalmicdrugs.com/openpr8

Ophthalmic Drugs Conference
18th – 20th November 2019
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
EXPERIMENTICA | ProMed Pharma

Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / amalick@smi-online.co.uk

Media enquiries contact Neill Howard +44 (0) 207 827 6164 / nhoward@smi-online.co.uk

--END—

45 Curlew Street

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novel Drug Delivery to be discussed at SMi’s Ophthalmic Drugs Conference and Focus Day 2019 here

News-ID: 1854397 • Views: 275

More Releases from SMI

Senior US officials from fuel policy teams and combat wings to present at Milita …
SMi reports: Senior US officials will be presenting at the 21st Annual Military Airlift Air-to-Air Refuelling conference in Seville, this December Air-to-air refuelling remains a key mission multiplier, utilised extensively in Operation Inherent Resolve to extend flight times for bombing runs against ISIS. As the US Air Force explores the greater utilisation of commercial refuellers for CONUS operations to free military assets for combat and international deployment there is a critical
Senior experts to discuss Naval Mine Countermeasures at Unmanned Maritime System …
The challenge posed by potential adversary mining capabilities is real and growing. For all navies, there is only one way to completely “Take the sailor out of the minefield,” and that is to leverage unmanned technologies to hunt and destroy mines from a distance.* By embracing technological advancements in unmanned systems, such as UUVs and USVs, they could sweep large portions of the sea while minimizing the risk to sailors. For
Military Robotics and Autonomous Systems 2020 announced as a Virtual Event
SMi Reports: Due to the ongoing challenges surrounding COVID-19, Military Robotics and Autonomous Systems in September will now run as a virtual event. With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the 3rd annual Military Robotics and Autonomous Systems Conference on the 2nd-3rd September 2020 into a fully interactive virtual meeting. All attendance by military and government will be free of charge
04-07-2020 | Health & Medicine
SMI
Associates of Cape Cod Webinar on Recombinant Chromogenic Assay as Alternate Met …
SMi Reports: Associates of Cape Cod to host an online webinar taking place on Wednesday 29th April 2020. SMi Group is delighted to announce a free webinar led by Associates of Cape Cods on 'Recombinant Chromogenic Assay as Alternate Methods for Bacterial Endotoxins Test (BET)' taking place on 29th April 2020 at 10am EDT (3pm BST - UK time). The webinar will aim to review the global perspective on the use

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning